Investor Relations

Company Overview

Skye Bioscience (Nasdaq: SKYE) is a biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Backed by specialist life science investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). Skye expects interim and topline data from its Phase 2 study in 2025.

Upcoming Event

European Congress on Obesity

IR Contacts

Headquarters

Skye Bioscience, Inc.
11250 El Camino Real
Suite 100
San Diego, CA 92130

Investor Relations

SKYE Investor Relations
T: (858) 410-0266
ir@skyebioscience.com

Transfer Agent

Broadridge Corporate Issuer Solutions, LLC
P.O. Box 1342
Brentwood, NY 11717
T: 303-974-3386
shareholder@broadridge.com
https://www.shareholder.broadridge.com